Other Phase II trials are currently underway in patients with CD25+ Chronic Lymphocytic Leukemia (CLL), Cutaneous T cell lymphoma (CTCL) and Hairy Cell Leukemia (HCL). This evidence concerns the gene IL2RA and hairy cell leukemia.